Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cinobufacini is a traditional Chinese medicine derived from the skin and parotid glands of the toad Bufo bufo gargarizans Cantor. It is used primarily as an antitumor agent in China and has been formulated as both an injection and capsule. The main active ingredients include bufalin, bufogenin, telocinobufagin, desacetylcinobufagin, arenobufagin (in capsules), and bufothionine (notably in injections). Cinobufacini exerts its anticancer effects through multiple mechanisms including inhibition of cell proliferation, induction of apoptosis and cell cycle arrest in tumor cells, disruption of cancer angiogenesis, reversal of multidrug resistance, immune modulation, and regulation of several signaling pathways such as PI3K-Akt/AKT-mTOR-NF-κB-JAK-STAT-PIN1-YAP/TAZ. It has demonstrated efficacy against various cancers including gastric cancer[1], triple-negative breast cancer[2], osteosarcoma[4], among others. The product is animal-derived (toad secretion) and widely used clinically in China for adjunctive therapy with chemotherapy or as monotherapy for malignant neoplasms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cinobufacini.